Drug intelligence / Profile preview

Iminodyn-22

Development stage: Unknown
Lead developer: Children's Medical Research Institute
Modality: Small Molecules

Overview

**Iminodyn-22** is a potent, cell-permeable small molecule inhibitor of dynamin I and II, targeting the GTPase Allosteric Site (GAS) domain with IC50 values of 450 nM for dynamin I and 390 nM for dynamin II. It exhibits uncompetitive inhibition with respect to GTP, effectively blocking receptor-mediated endocytosis in cells while inhibiting enzymatic GTPase activity. Developed from the iminochromene chemical series as part of the Iminodyn™ toolbox, it serves as a research tool for studying dynamin-dependent processes such as clathrin-mediated endocytosis, phagosome scission, F-actin assembly, and viral entry, and is sold under exclusive license from Children’s Medical Research Institute and Newcastle Innovation Ltd.[1][7][12][14]

Brand names: Iminodyn-22™

Targets

DNM1 (Dynamin 1)DNM2 (Dynamin 2)

Beyond the preview

Go deeper on Iminodyn-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iminodyn-22.

Explore the full profile